When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Câncer de ovário

Última revisão: 20 Aug 2025
Última atualização: 12 Mar 2025

Resumo

Definição

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • massa pélvica
  • ascite
  • derrame pleural
Full details

Other diagnostic factors

  • sintomas gastrointestinais
  • urgência urinária e polaciúria
  • duração dos sintomas >3 meses
  • distensão abdominal
  • dor ou pressão pélvica/abdominal
Full details

Risk factors

  • mutações genéticas associadas com o câncer de ovário hereditário
  • idade mais avançada
  • história familiar de câncer de ovário, câncer de mama, câncer colorretal e/ou câncer de endométrio
  • nunca usou contraceptivos orais combinados
  • nuliparidade
  • obesidade
  • terapia hormonal
  • endometriose
Full details

Diagnostic investigations

1st investigations to order

  • ultrassonografia pélvica
  • CA-125
  • histopatologia
Full details

Investigations to consider

  • teste genético
  • PET, PET-CT ou PET/RNM
  • RNM
  • Tomografia computadorizada (TC)
  • testes de biomarcadores
Full details

Treatment algorithm

ACUTE

candidato à cirurgia, doença confirmada por histologia intraoperatória

não candidato à cirurgia, doença confirmada por biópsia

ONGOING

doença recorrente sensível à platina

doença resistente à platina recorrente ou refratária

Contributors

Authors

Sareena Singh, MD

Gynecologic Oncologist

Aultman Medical Group

Northeast Ohio Medical University

Canton

OH

Disclosures

SS declares that she has no competing interests.

Acknowledgements

Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.

Disclosures

JCC and AEA declare that they have no competing interests.

Peer reviewers

Michael P. Hopkins, MD, MEd

Chairman

Obstetrics and Gynecology

Northeast Ohio Universities of Medicine (NEOMED)

Rootstown

OH

Disclosures

MPH declares that he has no competing interests.

Ritu Salani, MD

Gynecologic Oncology Fellow

Johns Hopkins Medical Institutions

Baltimore

MD

Disclosures

RS declares that she has no competing interests.

Susan A. Davidson, MD

Associate Professor

Chief, Gynecologic Oncology

Department of Obstetrics & Gynecology (UCD)

University of Colorado Cancer Center

Aurora

CO

Disclosures

SAD declares that she has no competing interests.

Khadra Galaal, MBChB, MPH, MRCOG

Consultant Gynaecological Oncologist

Northern Gynaecological Oncology Centre

Queen Elizabeth Hospital

Gateshead

UK

Disclosures

KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.

Jill Tseng, MD

Assistant Clinical Professor of Gynecologic Oncology

University of California, Irvine

Orange

CA

Disclosures

JT declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer [internet publication].Full text

González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-48.Full text  Abstract

Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J Clin Oncol. 2025 Mar;43(7):868-91.Full text  Abstract

Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):61-85.Full text  Abstract

Tew WP, Lacchetti C, Kohn EC, et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878-81.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Câncer de ovário images
  • Differentials

    • Síndrome do intestino irritável (SII)
    • Metástases no ovário
    • Endometriose
    More Differentials
  • Guidelines

    • Suspected cancer: recognition and referral
    • Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update
    More Guidelines
  • Patient information

    Câncer de ovário: quais tratamentos funcionam?

    Câncer de ovário: o que é?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer